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Abstract
Background: Adenocarcinoma of the pancreas is one of the most aggressive cancer diseases affecting the human
body. Recent research has shown the importance of the perioperative phase in disease progression. Particularly
during this vulnerable phase, substances such as metamizole and paracetamol are given as general anesthetics
and postoperative analgesics. Therefore, the effects of metamizole and paracetamol on tumor progression should
be investigated in more detail because the extent to which these substances influence the carcinogenesis of pancreatic
carcinoma is still unclear. This study analyzed the influence of metamizole and its active metabolites MAA
(4-N-methyl-aminoantipyrine) and paracetamol on the proliferation, apoptosis, and necrosis of the pancreatic
cancer cell lines PaTu 8988t and Panc-1 in vitro.
Methods: Cell proliferation was measured by means of the ELISA BrdU assay and the rate of apoptosis by flow cytometry
using the Annexin V assay.
Results: Metamizole and paracetamol significantly inhibited cell proliferation in pancreatic cancer cells. After the addition of
metamizole to PaTu 8988t cells, the rate of apoptosis was reduced after 3 h of incubation but significantly increased after
9 h of incubation.
Conclusion: The oncogenic potential of pancreatic adenocarcinoma is mainly characterized by its extreme growth rate.
Non-opioid analgesics such as metamizole and paracetamol are given as general anesthetics and postoperative analgesics.
The combination of metamizole or paracetamol with cytotoxic therapeutic approaches may achieve synergistic effects.
Further studies are necessary to identify the underlying mechanisms so that new therapeutic options may be developed
for the treatment of this aggressive tumor.
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Background
Adenocarcinoma of the pancreas is one of the deadliest
cancers worldwide with an overall life expectancy of
6 months [1]. Over the past few years, important advances
have been made in the molecular and biological under-
standing of pancreatic carcinoma [2]. Unfortunately, how-
ever, the clinical outcome has not significantly changed
for patients with pancreatic carcinoma [3]. The main
reasons for the poor prognosis of pancreatic carcinoma
are early metastasis, so far insufficient diagnostic and
therapeutic options, as well as a high recurrence rate [4].
Pancreatic carcinoma is also known for its extremely rapid
growth [5]. A further therapeutic option apart from
chemotherapy or radiation treatment is surgical removal
of the tumor. However, investigations over the past few
years have shown that the perioperative period is a par-
ticularly vulnerable phase marked by facilitation of tumor
progression and metastasis [6]. The combination of surgi-
cal intervention, a perioperatively compromised immune
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system, and drug therapy increases the risk of tumor dis-
semination, thus exerting a negative impact on disease
progression in oncological patients [7, 8]. Precisely at this
vulnerable stage, substances such as metamizole and para-
cetamol are administered as anesthetics or postoperative
analgesics [9, 10]. However, the direct effects of these sub-
stances on the tumor progression and carcinogenesis of
pancreatic carcinoma are still unclear and require further
investigations.
Metamizole (dipyrone) is a pyrazol derivative that be-
longs to the group of non-acidic, non-opioid analgesics
[11]. In the organism, separation of the sulfonate group
and the associated methylene group activates the actually
effective substance 4-methyl-aminoantipyrine (MAA).
Metamizole is the preferred first-line non-opioid analgesic
in many parts of the world, such as most EU countries
and Latin American countries. However, other countries
such as the United States, the United Kingdom, Sweden,
and most recently India have banned metamizole because
of its side effects (amongst others, agranulocytosis,
leukopenia, and deterioration in renal function) [12, 13].
In these countries, patients are preferably given paraceta-
mol (acetaminophen), an aminophenol derivative.
How exactly metamizole or paracetamol work in the
organism remains unclear. The substances are known to
act as a cyclooxygenase-2 inhibitor [14, 15]. Cyclooxy-
genases catalyze the conversion of arachidonic acid to
endoperoxide, the pre-stages of prostaglandin, thromb-
oxane A2, and prostacyclin [16]. Another possibility dis-
cussed by scientists is involvement of the 5-HT or
opioid metabolism, the cGMP signal pathway, or block-
ade of TRPA1 ion channels [17–19]. The extent to
which metamizole or paracetamol influence the carcino-
genesis of pancreatic carcinoma is so far unclear.
Aim of this study was to analyze the influence of metami-
zole with its active metabolites MAA (4-N-methyl-ami-
noantipyrine) and paracetamol on the proliferation,
apoptosis, and necrosis of pancreatic cancer cell lines PaTu
8988t and Panc-1 in vitro.
Methods
Cell lines
The human pancreatic cancer cell lines PaTu 8988t and
Panc-1 were obtained from Professor Ellenrieder (Philipps
University of Marburg, Germany). The pancreatic cell line
PaTu 8988t was established from a liver metastasis of a pri-
mary pancreatic adenocarcinoma and grown in structural
characteristics of highly differentiated primary pancreatic
adenocarcinoma. In contrast, the human cell line Panc-1
was obtained from a pancreatic carcinoma of ductal origin
exhibiting a low level of differentiation.
PaTu 8988t and Panc-1 cells were maintained in
Dulbecco’s modified Eagle’s medium (Sigma-Aldrich),
which was supplemented with 10% fetal calf serum (FCS)
(Sigma-Aldrich) and 5% Myco Zap (Lonza Verviers SPRL).
Cells were cultured in humidified CO2 atmosphere (5%) at
37 °C and maintained in monolayer culture. Experiments
were done with cells at ~65–75% confluence.
Reagents
Metamizole was purchased from Fluka, MAA from
Sigma-Aldrich, and paracetamol from Merck. Final con-
centrations were obtained by diluting drugs in standard
growth media. All solutions were prepared freshly prior
to use.
Cell proliferation
For cell proliferation analysis the cell proliferation ELISA
BrdU (Roche applied science) was applied. In brief, cells
were incubated with 100 μL of the test compounds for
48 h (1–500 μM of metamizole, 1–500 μM of MAA,
1–1000 μM of paracetamol, or 250 μM of metamizole,
and 250 μM of paracetamol). 5 mM ASS was used for
positive control and standard culture medium was used
for negative control. After 32 h of incubation, cells were
additionally treated with BrdU labeling solution for the
last 16 h. After fixing the cells and denaturating DNA,
cells were incubated with Anti-BrdU-POD solution for
90 min. The antibody conjugates were removed in three
washing cycles. Immune complexes were detected by
means of TMB substrate for 15 min and quantified by
measuring absorbance at 405 nm and 490 nm. All tests
were performed in duplicates with 8 wells per treatment
group and repeated three times.
Apoptosis analysis
Apoptosis assays with Annexin V staining were con-
ducted according to the manufacturer’s instructions (BD
Pharming). In brief, PaTu 8988t and Panc-1 cells were
incubated with 250 μM of metamizole, MAA, paraceta-
mol or metamizole, and paracetamol. Standard growth
medium was used for negative control. After 0 h, 3 h, 6 h,
9 h, 12 h, 16 h, 24 h, or 48 h incubation time, floating cells
were preserved by decanting supernatant. Adherent cells
were rinsed with warm PBS (Sigma-Aldrich) and detached
by standard trypsinization. Afterwards, harvested and
floating cells were mixed, washed, and resuspended in
binding buffer at a final concentration of 105 cells/ml.
5 μL of FITC Annexin and 5 μL of propidium iodide were
added to 100 μL of the cell suspension containing 105
cells, followed by 15 min incubation at room temperature
protected from light. 400 μL of binding buffer were added
and cells were analyzed by flow cytometry using FACS
Calibur (BD Bioscience) and Cellquest Pro software (BD
Bioscience). All tests were performed in duplicates and re-
peated three times. 1 μM of staurosporine, an often
employed method for inducing apoptosis, was used as a
Malsy et al. BMC Pharmacology and Toxicology  (2017) 18:77 Page 2 of 7
positive control for the testing procedure and induced sig-
nificant apoptosis in the pancreatic cancer cells.
Statistical analysis
Results are expressed as mean ± SD. The non-parametric
Mann Whitney U-test was used for statistical evaluation of
the data. Differences were considered statistically significant
at p values of <0.05. IBM SPSS Statistics (Vs. 23; IBM New
York, US) and Excel Vs. 2013 (Microsoft, Redmond, USA)
packages were employed for statistical analysis.
Results
Cell proliferation behavior
The pancreatic cancer cell lines PaTu 8988t and Panc-1
were either stimulated with 1–500 μM of metamizole
(a), 1–500 μM of MAA (b), 1–1000 μM of paracetamol
(c), or 250 of μM metamizole, and 250 μM of paraceta-
mol (d) for 48 h.
As a result, proliferation was significantly inhibited in
the PaTu 8988t cell line after incubation with 1–500 μM
of metamizole (Fig. 1a) and 1–1000 μM of paracetamol
(Fig. 1c). In PaTu 8988t cells, the combination of
250 μM of metamizole and 250 μM of paracetamol also
significantly reduced cell growth (Fig. 1d).
In the pancreatic cancer cell line Panc-1, proliferation
was significantly inhibited with concentrations of 1 μM,
10 μM, 100 μM, and 250 μM of metamizole (Fig. 1a). A
further slight inhibition was achieved with 10 μM of
MAA (Fig. 1b) and 1 μM of paracetamol in comparison
to the untreated control group (Fig. 1c). No other sig-
nificant changes in the proliferation rate were observed
using the other concentration.
Analysis of apoptosis and necrosis
The Annexin V staining apoptosis assay was used to deter-
mine whether stimulation with metamizole, MAA, and
paracetamol or the combination of metamizole and para-
cetamol caused apoptosis or necrosis in the pancreatic
cancer cell lines PaTu 8988t (Fig. 2) and Panc-1 (Fig. 3).
In the pancreatic cancer cell line PaTu 8988t, incuba-
tion with metamizole (a) and MAA (b) for 3 h (Fig. 2)
reduced the apoptotic cell fraction phase to 70% and
68% compared to untreated samples. In contrast, the
apoptosis rate was significantly increased after 9 h of in-
cubation with metamizole (a) and with the combination
of metamizole and paracetamol (d).
The other incubation times with metamizole and
MAA did not yield any changes in the apoptosis rate, as
well in Panc-1 pancreatic cancer cells. Paracetamol by it-
self did neither influence apoptosis nor necrosis in
pancreatic tumor cells.
Fig. 1 Effect of metamizole (a), MAA (b), paracetamol (c), and the combination of metamizole and paracetamol (d) on the proliferation of the pancreatic
cancer cell lines PaTu 8988t and Panc-1 after 48 h incubation. The proliferation rate was determined by means of proliferation BrdU assays. 100%
correspond to untreated control. (*) p< 0.05 in comparison to untreated control
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The positive control staurosporine induced apoptosis
in both cell lines in a time-dependent manner (Figure
not shown).
Discussion
The fact that many substances without any primary indi-
cation for treating tumor diseases show anti-tumoral be-
havior has been known for several years. Next to direct
effects on tumor cells, such as inhibition of cell prolifer-
ation or induction of apoptosis, clinical studies have also
shown the modulation of peri-tumoral stroma [20]. In-
teractions between the tumor and the surrounding
stroma play a vital role in tumor progression. Changes
in the surrounding tissue provide ideal conditions for
tumor growth, invasion, and subsequent metastasis [21].
Furthermore, inflammatory processes correlate with the
Fig 2 The effects of metamizole (a), MAA (b), paracetamol (c) and the combination of metamizole and paracetamol (d) on apoptosis in the pancreatic
cancer cell lines PaTu 8988t (Fig. 2) and Panc-1 (Fig. 3) in vitro. For apoptosis analysis, cancer cells were stained with Annexin V. (*) indicates statistical
significance at p < 0.05 compared to untreated control.
Fig 3 The effects of metamizole (a), MAA (b), paracetamol (c) and the combination of metamizole and paracetamol (d) on apoptosis in the pancreatic
cancer cell lines PaTu 8988t (Fig. 2) and Panc-1 (Fig. 3) in vitro. For apoptosis analysis, cancer cells were stained with Annexin V. (*) indicates statistical
significance at p < 0.05 compared to untreated control.
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development of precancerous lesions [22]. The fact that
the presence of inflammation facilitates the induction of
carcinogenesis has been described in many literature re-
ports [23]. A further independent risk factor for the
development of pancreatic carcinoma is chronic
pancreatitis [24].
Therefore, preventive effects have been expected from
non-steroid anti-inflammatory drugs (NSAIDs) because
of their anti-oxidative and anti-inflammatory properties
[25]. NSAIDs primarily inhibit activity of cyclooxygenase
(COX), thus influencing the synthesis of prostaglandins
as the central regulators of inflammation [26]. However,
the risk of pancreatic carcinoma is neither reduced by
the supplementation of antioxidants [27] nor by the ad-
ministration of non-steroidal anti-rheumatic drugs [28,
29]. Thus, the preventive intake of such medications is
not recommended in the current guidelines for the treat-
ment of pancreatic carcinoma [10].
In 1999, Tucker et al. showed increased COX-2 levels
in pancreatic carcinoma [30]. Similar increases were also
found in other human tumor cell lines [31], so that the
inhibition of cyclooxygenase 2 in the context of malig-
nancies has become the focus of tumor research, which
is shown by the number of publications in the literature
[32–34]. Yip-Schneider et al. found that the selective
COX-2 inhibitor celecoxib significantly inhibits cell pro-
liferation and induces apoptosis in pancreatic tumor
cells [35]. Li et al. showed that celecoxib inhibits prolif-
eration, invasion, and migration in Panc-1 pancreatic
tumor cell lines [36].
However, these results could not be confirmed in clin-
ical studies. In a phase II study, Ferrari et al. reported
that the combination of celecoxib and gemcitabine
yielded good clinical benefits and stable disease [37]. In
contrast, Dragovich et al. did not find any significant im-
provement in the survival time of patients with meta-
static cancer [38]. Thromboembolism is also a common
complication in patients with pancreatic carcinoma [39].
Intrinsic hypercoagulability and activating procoagulant
factors, such as the tissue factor (TF), platelet factor 4
(PF4), and plasminogen activator inhibitor type 1 (PAI-1)
often cause deep vein thrombosis, pulmonary embolism,
disseminated intravascular coagulation, portal vein throm-
bosis, or arterial thromboembolism [40]. Scientists have
discussed the activation of the coagulation systeme not
only as a probable concomitant condition of the disease
but as being directly related to facilitating tumor growth
and angiogenesis [41]. Because of their side effects,
COX-2 inhibitors may increase such adverse effects, thus
promoting tumor progression.
Metamizole and paracetamol do not have any selective
effect on cyclooxygenase and thus do not cause thrombo-
embolism. On the contrary, these substances have often
been reported to inhibit platelet aggregation [42, 43].
Therefore, it is all over more important to analyze the
effect of these two substances in clinically relevant concen-
trations on the carcinogenesis of pancreatic carcinoma.
The pyrazolone derivate metamizole is rapidly hydro-
lysed to its active metabolite 4-methylaminoantipyrine
(MAA). After oral administration of 1 g metamizole max-
imal plasma concentration of 17,3 +/− 7,5 mg/l was mea-
sured within 1–2 h. Peak plasma concentrations of MAA
of 62,2 +/− 15,9 mg/l (≈210–350 μM) were obtained after
intravenously injection of 1 g metamizole [44]. In a
pharmacological study patients received 1 g acetamino-
phen every 6 h intravenously. Peak plasma concentrations
after the first administration was 95 +/− 36 μM, after the
4th intravenously dose concentrations of 210 +/− 84 μM
were measured [45].
In our study, cell proliferation in PaTu 8988t pancreatic
tumor cell lines could be inhibited by administration of
metamizole. No dose-dependent effect could be observed
and even small doses seem to be sufficient. And also the
combination of 250 μM of metamizole and 250 μM of
paracetamol significantly reduced cell growth.
Interestingly, inhibition of proliferation was not possible
with 4-methylaminoantipyrine (MAA), the actually active
substance of metamizole. According to its mode of action,
metamizole in the organism is rapidly hydrolyzed to MAA
that is then acetylated to 4-formylaminoantipyrine (4-FAA),
4-aminoantipyrin (4-AA), or 4-acethylaminoantipyrine
(4-AAA). Here, all metabolites are pharmacologically active
[46], so that inhibition is possibly induced by 4-FAA, 4-AA,
or 4-AAA. In 2013, Shao et al. reported on the anti-
proliferative effects of metamizole in the cancer cell lines
A549 and HeLa [47]. The anti-proliferative effects of as-
pirin, indometacin, parecoxib, and ibuprofen in animal
models have also been described in the recent literature
[48, 49]. However, no clinical studies are yet available on
these substances as a support therapy in addition to
chemotherapy.
In the pancreatic tumor cell lines PaTu 8988t and
Panc-1, paracetamol has only a minor but still significant
anti-proliferative effect. Striking is that the proliferation
was significantly inhibited in the PaTu 8988t cell line
after incubation with 1–1000 μM of paracetamol but in
Panc-1 only an inhibition was achieved with 1 μM of
paracetamol in comparison to the untreated control
group. The difference of the two cell lines is the grade of
differentiation. The pancreatic cell line PaTu 8988t was
established from a liver metastasis of a primary pancre-
atic adenocarcinoma and grown in structural character-
istics of highly differentiated primary pancreatic
adenocarcinoma. In contrast, the human cell line Panc-1
was obtained from a pancreatic carcinoma of ductal
origin exhibiting a low level of differentiation.
The effect of paracetamol on carcinogenesis is even
more unanswered because of the limited data currently
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available in the literature. On the one hand, Tan et al.
did not find any connection between paracetamol and
the development of pancreatic carcinoma [50]. The in-
creased expression of differentiation markers in breast
cancer indicates that paracetamol changes tumor cells
into a more benign type with less tumor growth, limited
invasion capacity, and increased sensibility to anti-
tumoral substances [51]. In contrast, therapeutic doses
of paracetamol increase cell proliferation in lung cancer
[52] and stimulate DNA synthesis in breast cells sensi-
tive to estrogen [53]. Many more clinical studies are
necessary to identify the effect of these two substances
on carcinogenesis and to characterize their underlying
mechanisms.
Conclusion
The perioperative phase plays a vital role in the progres-
sion of tumor diseases due to the combination of peri-
operative immunosuppression, release of tumor cells by
surgical manipulation, and increased concentrations of
growth factors [6]. Particularly in this vulnerable phase,
a multitude of substances is administered as anesthetics
and postoperative analgesics, whose effects on tumor
progression have to be thoroughly investigated. In the
current study, the influence of metamizole, MAA, and
paracetamol on cell proliferation, apoptosis, and necrosis
could be shown in vitro in the pancreatic cancer cell
lines PaTu 8988t and Panc-1. Therapeutic doses of
metamizole and paracetamol inhibit proliferation in the
pancreatic cancer cell line PaTu 8988t. A combination of
metamizole or paracetamol with cytotoxic therapy may
achieve synergistic effects. Further studies are necessary
to identify the underlying mechanisms to be able to es-
tablish new therapeutic options for this aggressive type
of tumor.
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